• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

byConstance Wu
May 6, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Inclisiran, a small interfering RNA, therapy was shown to significantly lower levels of low-density lipoprotein (LDL) cholesterol compared to the placebo in adults with heterozygous familial hypercholesterolemia.

2. The reduction in LDL cholesterol levels, via inclisiran therapy, was shown to be similar to the reduction achieved with proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody therapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Current pharmacologic management of familial hypercholesterolemia includes high intensity statins and monoclonal antibodies directed against PCSK9. Both therapies have been shown to reduce LDL cholesterol but require frequent dosing regimens. The ORION-9 trial evaluated inclisiran, a novel small interfering RNA therapeutic that also acts on PCSK9, in a large patient cohort of adults with heterozygous familial hypercholesterolemia who had been treated with a maximally accepted statin therapy dose. The study found a significant decrease in LDL cholesterol from baseline in the inclisiran group compared to the placebo group.

Of note, while the majority of the patients were also taking a statin and ezetimibe, the regimens across participants was not consistent. Furthermore, the combined effects of various statins, ezetimibe, and inclisiran on LDL cholesterol was not separately analyzed. Nonetheless, this study is strengthened by the diagnostic measures used to assess the effect of inclisiran on LDL cholesterol levels. For physicians, these findings provided evidence for another therapy for patients who have failed high intensity statins and do not want frequent dosing regimens.

Click to read the study in NEJM

RELATED REPORTS

Prevalence of common chronic conditions in Medicare Advantage and traditional Medicare beneficiaries

Plozasiran reduces triglyceride levels in mixed hyperlipidemia

Urgent need for improved detection of pediatric familial hypercholesterolemia worldwide

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: familial hypercholesterolemiahyperlipidemiainclisirinLDLsmall interfering RNA (siRNA)
Previous Post

Blood pressure variability in early adulthood linked with adverse structural myocardial changes

Next Post

Retracted: Underlying cardiovascular disease associated with increased mortality in COVID-19 patients

RelatedReports

Chronic Disease

Prevalence of common chronic conditions in Medicare Advantage and traditional Medicare beneficiaries

February 25, 2025
Low circulating cholesterol in neonates linked with pyloric stenosis
Cardiology

Plozasiran reduces triglyceride levels in mixed hyperlipidemia

October 2, 2024
Tonsillectomy may have short-term benefits in recurrent throat infection
Cardiology

Urgent need for improved detection of pediatric familial hypercholesterolemia worldwide

February 2, 2024
High-intensity treadmill exercise may slow progression of motor symptoms in early Parkinson’s disease
Cardiology

Vascular Function Improvements Derived From Exercise Are Not Sex-Dependent

January 22, 2024
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

Retracted: Underlying cardiovascular disease associated with increased mortality in COVID-19 patients

Live attenuated vaccine less effective in recent influenza season

Decrease in influenza transmission with COVID-19 interventions in Hong Kong

Policy statement outlines recommendations on management of youth involved in the justice system during COVID-19 pandemic

Policy statement outlines recommendations on management of youth involved in the justice system during COVID-19 pandemic

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seventh cervical nerve neurotomy may augment speech therapy in patients with chronic aphasia post-stroke
  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.